Invivyd develops monoclonal antibodies to prevent or treat infectious diseases. This approach could be useful in tamping down the measles outbreaks that have been occurring due to under-vaccination
- Apr 22
- 1 min read
CSO Robert Allen describes Invivyd's approach and why antibodies can be a good approach, especially as it relates to being resistant to viral evolution. He walks us through the science and some potential use cases.
Chapters
His career - 0:00
A monoclonal approach - 1:50
Measles - 7:28
The science behind Invivyd - 11:10
Pandemic preparedness - 19:24
Advice to students - 20:50
.png){kind=logo}